MEET THE EXPERTS

Brian was promoted to CEO of Pyramid Biosciences in January 2022, after previously serving as the Company’s Chief Medical Officer.  Brian joined the Company from Bristol-Myers Squibb, where he most recently was Vice President and Development Leader for the relatlimab (anti-LAG3) immunotherapy program. In this capacity, Brian oversaw the development and commercialization strategy for this novel immunotherapy agent across a wide range of tumors. Brian brings over a decade of early-stage and late-stage development leadership experience in Oncology, including the design, execution and submissions leading to the first global approvals of OPDIVO (nivolumab, anti-PD1). Previously, Brian served as the Global Medical Affairs Head and Development Leader for three hematology products, OPDIVO, SPRYCEL (dasatinib), and EMPLICITI (elotuzumab). Prior to joining BMS, he led the early-stage clinical development for the BRAF inhibitor program at Hoffmann-La Roche. Brian is a Board-Certified Pediatric Hematologist-Oncologist, and received his MD and PhD degrees from Case Western Reserve University, and completed his fellowship training at the Children’s Hospital of Philadelphia (CHOP).

Jordan Leef is an entrepreneur and venture capitalist specializing in the healthcare industry. Jordan brings more than a decade of experience in life science venture creation and has served on the boards of over 20 companies as a director or observer.

Prior to founding Pyramid Biosciences, Jordan most recently served as an executive at two oncology companies, Metamark Genetics, which focused on urological cancers, and Interpace Diagnostics Group (Nasdaq: IDXG), which develops molecular diagnostic tests. He was also a Principal Venture Capitalist and member of the healthcare investment team at the publicly-traded venture capital firm, Safeguard Scientifics (NYSE: SFE).

Prior to Safeguard, Jordan served as a Senior Associate with MentorTech Ventures, a Philadelphia-based venture capital firm that invests in seed and early-stage companies. During his time at MentorTech, Jordan was also a Senior Associate for SVM Israel, investing in Israeli private equity and venture capital funds as well as selectively co-investing alongside those funds. Earlier in his investment career, Jordan was a Financial Analyst at the private equity firm Pharos Capital Group, where he worked as a member of the investment team to provide growth and later-stage capital for businesses in the healthcare, business services and technology industries. Before his career in venture capital, Jordan worked in the biotechnology equity research group at C.E. Unterberg, Towbin (presently known as Collin Stewart) and for Pfizer, Inc. (NYSE: PFE) in its US clinical operations and business development divisions.

Jordan Leef is a graduate of the Wharton School at the University of Pennsylvania, where he concentrated in healthcare management and policy.

Dr. Bowden serves as a senior medical advisor to Pyramid Biosciences where he brings more than ​20 years of experience in clinical drug development.  Previously, Dr. Bowden served as the Chief Medical Officer for Agios Pharmaceuticals, where he spearheaded the clinical development and FDA approval of TIBSOVO®.

Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech, Inc., a member of the Roche Group. During Dr. Bowden’s eight years at Genentech, he was responsible for the successful development of a number of novel targeted oncology medicines, including Zelboraf™ for patients with BRAF V600E positive melanoma and Tarceva™ for patients with EGFr activating mutation positive, non-small cell lung cancer. From 2003 to 2006, Dr. Bowden was the executive director for EMEA (Europe, Middle East, Africa) regions for Bristol-Myers Squibb. In this role, he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development, Phases I-III at Pharmacia Corporation and Janssen Pharmaceutical, Inc. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center where he participated in numerous industry and cooperative group trials. Dr. Bowden received his medical degree from Hahnemann University School of Medicine in Philadelphia followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology, and he serves on the board of directors at Ziopharm Oncology Inc.

Deb Chapman joined the Company in 2021 and has nearly three decades of clinical research and operations experience.  Previously, Deb has contributed to the clinical development of several FDA approved oncology drugs, including Doxil and Avastin.  Prior to joining Pyramid Bio, Deb served as a clinical consultant to numerous early-stage pharmaceutical and biotechnology companies, including Zogenix Inc., Prothena Biosciences, and Aduro Biotech. Early in her career, Deb held roles of increasing responsibility at Gilead Sciences, Bristol Myers’ Squibb and Genentech.  Deb holds a B.S. degree in biology from Santa Clara University.